[225Ac]Ac-DOTATATE
Sponsors
Peking University Cancer Hospital & Institute
Conditions
Neuroendocrine NeoplasmSCLC, Extensive Stage
Phase 1
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
RecruitingNCT06732505
Start: 2024-09-29End: 2026-03-31Target: 36Updated: 2025-06-26
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
RecruitingNCT07413042
Start: 2026-01-20End: 2028-06-30Target: 24Updated: 2026-02-17